Literature DB >> 24263798

The effects of untreated and treated HIV infection on bone disease.

Aoife G Cotter1, Patrick W G Mallon.   

Abstract

PURPOSE OF REVIEW: Low bone mineral density (BMD) is common in those with HIV, associated with higher bone turnover and a higher prevalence of fractures. This review explores low BMD in HIV, focusing on underlying mechanisms and relationships between low BMD and HIV infection, immune dysfunction, and antiretroviral therapy (ART). RECENT
FINDINGS: Greater reductions in BMD accompanying reductions in HIV viremia at initiation of first-line or second-line ART suggest an important role for immune- or viral-mediated mechanisms in its pathogenesis.
SUMMARY: As bone metabolism is part-regulated by T cells and B cells, we propose that earlier initiation of ART at higher CD4 T-cell counts may attenuate BMD loss by abrogating immune- and viral-mediated disturbances in bone metabolism that accompany ART initiation. Further pathogenesis-based research is required in this field, focusing on the complex interaction between virus, immune system, ART, and bone metabolism.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24263798     DOI: 10.1097/COH.0000000000000028

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  21 in total

Review 1.  The protease inhibitors and HIV-associated bone loss.

Authors:  Caitlin A Moran; M Neale Weitzmann; Ighovwerha Ofotokun
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

2.  Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.

Authors:  L T Vernon; Plp Jayashantha; M M Chidzonga; M C Komesu; R G Nair; N W Johnson
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

3.  Bone degradation machinery of osteoclasts: An HIV-1 target that contributes to bone loss.

Authors:  Brigitte Raynaud-Messina; Lucie Bracq; Maeva Dupont; Shanti Souriant; Shariq M Usmani; Amsha Proag; Karine Pingris; Vanessa Soldan; Christophe Thibault; Florence Capilla; Talal Al Saati; Isabelle Gennero; Pierre Jurdic; Paul Jolicoeur; Jean-Luc Davignon; Thorsten R Mempel; Serge Benichou; Isabelle Maridonneau-Parini; Christel Vérollet
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-20       Impact factor: 11.205

4.  Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.

Authors:  Edgar Turner Overton; Ellen S Chan; Todd T Brown; Pablo Tebas; Grace A McComsey; Kathleen M Melbourne; Andrew Napoli; William Royce Hardin; Heather J Ribaudo; Michael T Yin
Journal:  Ann Intern Med       Date:  2015-06-16       Impact factor: 25.391

Review 5.  Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient.

Authors:  Jennifer Hoy
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

6.  Changes in bone turnover markers with HIV seroconversion and ART initiation.

Authors:  Laurence Slama; Susheel Reddy; John Phair; Frank J Palella; Todd T Brown
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

7.  Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection.

Authors:  Ighovwerha Ofotokun; Kehmia Titanji; Aswani Vunnava; Susanne Roser-Page; Tatyana Vikulina; Francois Villinger; Kenneth Rogers; Anandi N Sheth; Cecile Delille Lahiri; Jeffrey L Lennox; M Neale Weitzmann
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

8.  Treatment of Human Immunodeficiency Virus Infection With Tenofovir Disoproxil Fumarate-Containing Antiretrovirals Maintains Low Bone Formation Rate, But Increases Osteoid Volume on Bone Histomorphometry.

Authors:  Janaina Ramalho; Carolina Steller Wagner Martins; Juliana Galvão; Luzia N Furukawa; Wagner V Domingues; Ivone B Oliveira; Luciene M Dos Reis; Rosa Mr Pereira; Thomas L Nickolas; Michael T Yin; Margareth Eira; Vanda Jorgetti; Rosa Ma Moyses
Journal:  J Bone Miner Res       Date:  2019-07-03       Impact factor: 6.390

Review 9.  Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities.

Authors:  Ivona Pandrea; Alan Landay; Cara Wilson; Jennifer Stock; Russell Tracy; Cristian Apetrei
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

10.  Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+ T-cell ratio: effect of naïve and memory T-cell subsets.

Authors:  Willard Tinago; Elizabeth Coghlan; Alan Macken; Julie McAndrews; Brenda Doak; Charlotte Prior-Fuller; John S Lambert; Gerard J Sheehan; Patrick W G Mallon
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.